Market Closed -
Nasdaq
04:00:00 2024-06-12 pm EDT
5-day change
1st Jan Change
2.275
USD
+0.66%
-1.52%
-1.94%
Presentation Operator MessageOperator (Operator)Good morning, and welcome to the Mersana Thera...
Transcript : Mersana Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 08:00 AM
Jun. 12
Transcript : Mersana Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09
Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q1 Revenue $9.2M, vs. Street Est of $8.5M
May. 09
MT
Mersana Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 09
CI
North American Morning Briefing : Markets on Hold -2-
Mar. 20
DJ
JPMorgan Upgrades Mersana Therapeutics to Neutral From Underweight, Price Target is $5
Mar. 19
MT
Mersana Therapeutics, Inc.(NasdaqGS:MRSN) added to S&P Biotechnology Select Industry Index
Mar. 17
CI
Truist Securities Upgrades Mersana Therapeutics to Buy From Hold, Price Target is $9
Feb. 29
MT
Guggenheim Upgrades Mersana Therapeutics to Buy From Neutral, Price Target is $7
Feb. 29
MT
Wedbush Upgrades Mersana Therapeutics to Outperform From Neutral, Notes Increased Confidence in Program; Adjusts PT to $7 From $2
Feb. 29
MT
Transcript : Mersana Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Feb. 28
Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q4 Revenue $10.7M, vs. Street Est of $14.8M
Feb. 28
MT
Mersana Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Feb. 28
CI
Mersana Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Feb. 28
CI
Transcript : Mersana Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 11:15 AM
Jan. 11
Mersana Therapeutics Gears Up for Milestones in Cancer Drug Trials
Jan. 05
MT
Mersana Therapeutics, Inc. Announces Business Updates
Jan. 05
CI
Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from NASDAQ Biotechnology Index
Dec. 15
CI
North American Morning Briefing : China Outlook -2-
Dec. 05
DJ
Citigroup Upgrades Mersana Therapeutics to Buy From Neutral, Raises Price Target to $5 From $1
Dec. 04
MT
Mersana Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 07
CI
Transcript : Mersana Therapeutics, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Nov. 07
Mersana Therapeutics Shares Rise 8% After FDA Lifts Clinical Hold for Cancer Treatment
23-10-31
DJ
Mersana Says FDA Lifts Clinical Hold on Gastric-Cancer Treatment Phase I Trial
23-10-31
DJ
Mersana Therapeutics, Inc. Announces FDA Has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056
23-10-31
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.
More about the company
Last Close Price
2.275
USD
Average target price
6.375
USD
Spread / Average Target
+180.22%
Consensus
1st Jan change
Capi.
-1.94% 278M +16.93% 123B +17.01% 111B -7.23% 23.63B +1.98% 22.58B -14.29% 17.26B -6.79% 17.6B -37.63% 17.61B +2.17% 13.55B +24.42% 11.34B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1